Cocrystal Pharma (Cocrystal Pharma) Float Percentage Of Total Shares Outstanding : 76.28% (As of May. 01, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cocrystal Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cocrystal Pharma's float shares is 7.76 Mil. Cocrystal Pharma's total shares outstanding is 10.17 Mil. Cocrystal Pharma's float percentage of total shares outstanding is 76.28%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cocrystal Pharma's Insider Ownership is 43.85%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cocrystal Pharma's Institutional Ownership is 4.89%.

Cocrystal Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Cocrystal Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	7.76	/	10.17
	=	76.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cocrystal Pharma (Cocrystal Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (NAS:COCP) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

8CC:Germany

Address

19805 North Creek Parkway, Bothell, WA, USA, 98011

Website

https://www.cocrystalpharma.com

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Executives

Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Frost Phillip Md Et Al	director, 10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Raymond F Schinazi	director, 10 percent owner	1860 MONTREAL ROAD, TUCKER GA 30084
Anthony J Japour	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
Todd R. Brady	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
James Joseph Martin	officer: Interim CFO	4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Curtis Dale	officer: INTERIM CFO	1860 MONTREAL ROAD, TUCKER GA 30084
Douglas L Mayers	officer: CHIEF MEDICAL OFFICER	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Walt Addison Linscott	officer: GENERAL COUNSEL AND SECRETARY	1860 MONTREAL ROAD, TUCKER GA 30084
Jeffrey A Meckler	director	740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
David S Block	director
Hsiao Jane Ph D	director	4400 BISCAYNE BLVD, MIAMI FL 33137
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger D. Kornberg	director	345 WALSH ROAD, ATHERTON CA 94027